SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Emcure Pharmaceuticals Ltd

BSE: 544210 NSE: EMCURE ISIN: INE168P01015
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Emcure Pharmaceuticals Ltd belong to?
Emcure Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Emcure Pharmaceuticals Ltd a good quality company?
Emcure Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Emcure Pharmaceuticals Ltd undervalued or overvalued?
Emcure Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Emcure Pharmaceuticals Ltd a good buy now?
Emcure Pharmaceuticals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd revenue growth is 25.3% for FY-2025 , which is above its 5 year CAGR of 13% , indicating faster growth.
Q.2 Gross Profit margin of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 14.9% for FY-2025 , which is in line with its 5 year median of 14.9% , indicating stable margins.
Q.3 Operating Profit Margin of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 14.22% for FY-2025 , which is in line with its 5 year median of 14.22% indicating stable margins.
Q.4 Net Profit Margin of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Net Profit Margin is 7.24% for FY-2025 , is in line with with its 5 year median of 7.24%, indicating stable margins.
Current Level Historic Median
Gross Profit Margin 14.9 14.9
Operating Profit Margin 14.22 14.22
Net Profit Margin 7.24 7.24
Q.5 Return on Asset of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Return on Asset is 6.23%, which is in line with its 5 year historical median of 6.23%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Return on equity is 12.86% for FY-2025 , which is in line with its historical median of 12.86%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Return on capital employed is 15.4% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Cash conversion cycle is 76 days, below its historical median of 95 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.86 0.75
ROE 12.86 12.86
ROCE 15.4 15.4
Cash Conversion Cycle 76 days 95 days
Q.9 Debt to Equity ratio of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Debt-to-Equity ratio is 0.22 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd Debt to cash flow from operations is 1.17 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Emcure Pharmaceuticals Ltd?
Promoters hold 77.87% of the Emcure Pharmaceuticals Ltd, with 0.04% of their stake pledged, indicating low pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Emcure Pharmaceuticals Ltd vs industry peers?
Emcure Pharmaceuticals Ltd revenue CAGR is 13.02% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 4,381.9 137.1
Gross Profit 652.9 15.1
Operating Profit 623 16
Net Profit 317 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.86 0.8
ROE 12.86 8.91
ROCE 15.4 11.59
Cash Conversion Cycle (days) 76.07 76

Valuation & price assessment

Q.1 Stock return of Emcure Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 77.44% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - 77.4%
Q.3 Valuation ratios of Emcure Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 48.38 0.00 40.28
Price to Book 8.9 0.00 2.77
Price to Sales 6.12 0.00 2.65
EV to EBITDA 26.53 0.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Pfizer
6. Wockhardt
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Acutaas Chemicals
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×